Literature DB >> 10331614

Fragile X premutations and (TA)n estrogen receptor polymorphism in women with ovarian dysfunction.

M Syrrou1, I Georgiou, P C Patsalis, I Bouba, G Adonakis, G N Pagoulatos.   

Abstract

We studied five groups of women with ovarian dysfunction for the CGG expansion in FMR1 and a (TA)n polymorphism in the estrogen receptor gene: a) poor responders to ovarian stimulation as part of in vitro fertilization (n = 13); b) women with familial premature ovarian failure (POF) (n = 7); c) sporadic cases with POF (n = 16); d) FRAXA premutation carriers with POF (n = 7); and e) FRAXA premutation carriers without POF (n = 9). FRAXA premutation was found in one woman with familial POF. A significant association of familial POF and FRAXA premutation carriers with POF having low copy of the (TA)n polymorphism as compared to controls was observed. Our preliminary data suggest a potential role of the estrogen receptor in POF, and it may influence the variable age of menopause of the FRAXA premutation carriers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331614

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

Review 1.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

2.  Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer.

Authors:  Andrei Anghel; Marius Raica; Catalin Marian; Sorin Ursoniu; Oana Mitrasca
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

3.  Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.

Authors:  Chang Hoon Yim; Jong Tae Choi; Hyun Ah Choi; Young Soon Kang; In Gul Moon; Hyun Koo Yoon; In Kwon Han; Dae Hee Kang; Ki Ok Han
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.